We are developing a portfolio of novel machine learning disease prediction algorithms
At AlgoDx, the premise underlying all our research is the final product’s reliability. Our research methods are based on gold standards used in medical device and pharmaceutical development. We use a scientific, evidence-based approach with regulatory requirements in mind. Our research projects are designed to generate robust clinical evidence for product claims, covering clinical and health-economic benefits as well as potential risks.
AlgoDx Clinical Pipeline as of May 2021
|
Pre-clinical R&D
|
Regulatory Clearance
|
Clinical Validation
|
PMCF*
|
|
|---|---|---|---|---|
| NAVOY® Sepsis |
||||
| NAVOY® Acute Kidney Injury |
||||
| FLARE-UPS in Inflammatory Bowel Disease (co-development with global pharmaceutical) |
||||
| Hepatitis B Precision medicine (co-development with Swedish national consortium) |
||||
|
Ongoing
Complete * Post-Marketing Clinical Follow-up |
||||
Clinical Trials – AlgoDx sponsored clinical research
For more information on our ongoing clinical trials, visit clinicaltrials.gov
ExPRESS
Early Prediction of Sepsis in Hospitalized Patients Using a Machine Learning Algorithm, a Randomized Clinical Validation Trial.
Protocol number: NCT04570618